跳至主要内容

Medicilon's pharmacology models for inflammatory-immune diseases

 Medicilon's pharmacology models for inflammatory-immune diseases

Inflammatory immune diseases have gained much attention as the incidence has grown bigger each year. The diseases can affect many parts of human bodies and reduce the quality of life drastically. Yet the diagnoses can be frustrating and stressful because no one is sure what causes such diseases.

The preclinical pharmacology department of Medicilon has been deeply involved in this field for many years, and has provided a variety of stable and reliable animal models for different targets and pathways for the evaluation of inflammatory immune disease treatments in order for the successful clinical transformation.

At present, as the pathogenesis of inflammatory and immunological diseases is unclear, there are few effective therapeutic drugs available in clinical practice. In such a context, the appropriate preclinical research techniques and models are required to help companies and researchers further develop and evaluate new drugs. Our Preclinical Pharmacodynamics Department has been deeply involved in this field for years, developing reliable animal-based efficacy evaluation models aimed at different targets and pathways, thus facilitating the clinical transformation of new drugs.

RA, rheumatoid arthritis

RA is a chronic and systemic inflammatory autoimmune disease mainly targeting joints. It has a very high disability rate. The cause of the disease is still unclear.

Medicilon models that you can choose from:

  • CIA mice/rats Models

  • CFA rats Models

Major Endpoints

Foot Volume

CIA Models  and CFA Models

        △CIA Models                                                    △CFA Models

Arthritis Index

CIA Models

△CIA Models

Cytokine Expression

CFA Models

△CFA Models

Other arthritis models:

Carrageenan-induced acute arthritis mice/rats models

Uric acid sodium induced gouty arthritis rats models

EAE, experimental allergic encephalomyelitis

EAE, experimental allergic encephalomyelitis

Psoriasis

Psoriasis is a common skin disease that occurs worldwide. It is a disease that is not only closely related to genetics, but also obviously related to the environment.

Medicilon establishes diverse models that captures key features of psoriasis, including:

  • IL-23 induced hyperplasia of auricle epidermis mice models

  • Imiquimod induced psoriasis mice models

  • Vaginal epithelial mitosis mice models

  • Tale exfoliation mice models

Major Endpoints:

Skin thickness

Pathological skin change of Imiquimod induced psoriasis mice

△Pathological skin change of Imiquimod induced psoriasis mice

Ear thickness

△Pathological skin change of IL-23 induced psoriasis mice

Skin colligation score of mice

△Pathological skin change of Imiquimod induced psoriasis mice

Pathological skin score

△Imiquimod induced psoriasis                 △IL-23 induced psoriasis

AD, atopic dermatitis

Atopic dermatitis is a chronic, recurring, inflammatory skin disease, often accompanied by other symptoms such as allergic rhinitis, asthma, eczema, etc. The cause of the disease is not yet clear and there is no cure.

The disease related models include:

  • DNFB induced chronic dermatitis mice models

  • DNFB & OX induced chronic dermatitis mice models

  • Phorbol ester induced acute eczema mice models

  • DNFB induced acute eczema mice models

Skin score

△DNFB induced chronic dermatitis

Skin thickness

△DNFB induced chronic dermatitis

IBD, Infectious Bursal Disease

Inflammatory bowel disease (IBD) is a group of unexplained chronic intestinal inflammatory diseases. Due to the increasing incidence, it has become a common digestive system disease in our country. It mainly refers to ulcerative colitis and Crohn’s Disease.

Our IBD models includes:

TNBS induced IBD rats models

DSS induced IBD mice models

△Colon length of TNBS induced IBD rats models

△Colon weight of DSS induced IBD mice models

评论

此博客中的热门博文

Medicilon and Binhui Biopharmaceutical Have Reached a Strategic Collaboration to Jointly Draw a New Blueprint for the Development of New Biological Drugs

  On March 18, Medicilon and Binhui Biopharmaceutical (Binui Bio) announced a strategic collaboration.  The two parties will work together to jointly explore the possibilities in cutting-edge fields such as oncolytic viruses, nucleic acid drugs and protein drugs. Gather and Work Together to Create Advantages      Facilitate the Research and Development of Oncolytic Viruses, Nucleic Acids, Proteins and Other Drugs As a one-stop biopharmaceutical comprehensive preclinical R&D service CRO, Medicilon has been developing and accumulating for 20 years, always adhering to the spirit of innovation, and has successfully constructed bi/multi-specific antibodies,  ADCs ,  mRNA vaccines ,  small nucleic acid drugs ,  PROTAC , and  CGT technical service platform  that have helped 421 INDs obtain clinical approval.  It is this outstanding achievement that has earned Medicilon wide recognition in the industry and laid a solid foundation f...

The Launch Meeting was Held by Medicilon and DAC Biotech of the Contract Research on ADC Preclinical Study

  Chuansha, Shanghai, Nov. 8th, 2019 — Medicilon held the launch meeting with Hangzhou DAC Biotech Co., Ltd to initiate the   preclinical study   of the antibody-drug-conjugate (ADC)  DXC005, including the   pharmacology study ,   DMPK study   and the   safety evaluation . Medicilon has previously completed integrated  preclinical research  on ADC drugs cooperating with DAC Biotech and other companies. Two of them has been approved by NMPA and entered Phase I clinical trials. About Hangzhou DAC Biotech Co., Ltd Hangzhou DAC Biotech, Co., Ltd was officially registered in HEDA Area, Hangzhou City, Zhejiang Province, China around the end of Year 2012, and is located nearby the bank of beautiful Qiantang River. The company focuses on developing conjugate of monoclonal antibody and small molecular cytotoxic drug, both of which are banded together with smart linkers. About Antibody-Drug-Conjugate (ADC) ADCs ...

A Nickel-Catalyzed Reductive Alkylation of Aryl Bromides and Chlorides for Sp3-Sp2 Bond Formation

  In 2012, a nickel-catalyzed reductive alkylation method of aryl bromides and chlorides was reported. Under the optimized conditions, a variety of aryl and vinyl bromides as well as active aryl chloride can be reductively coupled with alkyl bromides in high yields. The protocols were highly functional-group tolerant and the reactions were not air or moisture sensitive. The reaction showed different chemoselectivity than conventional cross-coupling reactions. Substrates bearing both anelectrophilic and nucleophilic carbon resulted in selective coupling at the electrophilic carbon (R-X) and no reaction occurred at the nucleophilic carbon (R-[M]). The 2010 Nobel Prize in Chemistry was awarded for the Pd-catalyzed cross-coupling, and in the past decade the progress in cross-coupling has not only had a significant impact on academic research but has also influenced the industrial synthetic application. The transition-metal-catalyzed union of nucleophilic organo-boronic acids with elect...